Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.
2.
3.

Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.

Gotto AM Jr, Farmer JA.

Nat Clin Pract Cardiovasc Med. 2006 Dec;3(12):664-72. Review.

PMID:
17122799
4.

[Statins and the risk of diabetes].

Simonyi G.

Orv Hetil. 2013 Oct 27;154(43):1691-5. doi: 10.1556/OH.2013.29732. Review. Hungarian.

PMID:
24140507
5.

Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy.

Rapezzi C, Biagini E, Bellis P, Cafiero M, Velussi M, Ceriello A, Cooke RM, Schweiger C; EASY Investigators.

J Cardiovasc Med (Hagerstown). 2008 Sep;9(9):878-87. doi: 10.2459/JCM.0b013e3282f56513.

PMID:
18695423
6.

[Clinical practice guidelines for the management of dyslipidemia in chronic kidney disease].

Shoji T.

Nihon Jinzo Gakkai Shi. 2013;55(7):1267-75. Review. Japanese. No abstract available.

PMID:
24288962
7.

[Are therapeutic LDL goals justified? Controversies between the European and American guidelines].

Bertomeu-Martínez V.

Medwave. 2016 Dec 30;16(Suppl4):e6825. doi: 10.5867/medwave.2016.6825. Review. Spanish.

PMID:
28055995
8.

[The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].

Olsson AG.

Lakartidningen. 2011 Nov 23-29;108(47):2442-3. Swedish. No abstract available.

PMID:
22468387
9.

[Adherence to statins: updates and practical proposals].

Bauwens M, Schneider MP, Nanchen D.

Rev Med Suisse. 2016 Mar 2;12(508):445-8, 450. French.

PMID:
27089601
10.

Newer, lower, better? Lipid drugs and cardiovascular disease--the continuing story.

Wierzbicki AS.

Int J Clin Pract. 2007 Jul;61(7):1064-7. No abstract available.

PMID:
17577288
11.

[Treatment of dyslipidemia in 2014: European versus American guidelines].

Radermecker RP.

Rev Med Suisse. 2014 Aug 27;10(439):1534-7. French.

PMID:
25272669
12.

[Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].

Olsson AG.

Lakartidningen. 2011 Jun 1-14;108(22-23):1240-3. Review. Swedish. No abstract available.

PMID:
21786498
13.

High-dose statin therapy: benefits and safety in aggressive lipid lowering.

Toth PP, Davidson MH.

J Fam Pract. 2008 May;57(5 Suppl High-Dose):S29-36. Review. No abstract available.

PMID:
18662521
14.

Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.

Schima SM, Maciejewski SR, Hilleman DE, Williams MA, Mohiuddin SM.

Expert Opin Pharmacother. 2010 Apr;11(5):731-8. doi: 10.1517/14656560903575639. Review.

PMID:
20210682
15.
16.

Assessment of low-density lipoprotein targets.

Whayne TF Jr.

Angiology. 2013 Aug;64(6):411-6. doi: 10.1177/0003319712451115. Epub 2012 Jun 25. Review.

PMID:
22734087
17.

[Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].

Båvenholm P, Attvall S, Nilsson PM.

Lakartidningen. 2006 Aug 30-Sep 5;103(35):2462-6. Review. Swedish. No abstract available.

PMID:
17002161
18.

Risk of diabetes with statins must be monitored in each patient.

Bifulco M.

BMJ. 2013 Jul 2;347:f4170. doi: 10.1136/bmj.f4170. No abstract available.

PMID:
23820519
19.

[Treatment with statins].

Bogsrud MP, Reikvam Å, Retterstøl K.

Tidsskr Nor Laegeforen. 2013 Jun 25;133(12-13):1316-9. doi: 10.4045/tidsskr.12.0825. Norwegian. No abstract available.

20.

Supplemental Content

Support Center